GlassScriptPhysician profile
Vyacheslav Isakov
NPI 1407826803
$1,421.26
in general payments reported to CMS, 2019-2025
19 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $128 · 2021: $11.75 · 2024: $186 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.17 | 2019-2025 | |
| Lilly USA, LLC | $244.97 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $154.71 | 2019-2025 | Farxiga |
| Abbvie INC. | $125.19 | 2019-2024 | |
| Novo Nordisk INC | $90.88 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $68.00 | 2019-2020 | |
| Amgen INC. | $60.08 | 2019-2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $50.48 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.67 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $44.41 | 2024-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $40.54 | 2025 | Watchman Access System |
| Merck Sharp & Dohme LLC | $38.81 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.06 | 2024-2025 | Xifaxan |
| Allergan, INC. | $34.99 | 2019 | |
| Astellas Pharma US INC | $26.63 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.04 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $17.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.69 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vyacheslav Isakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.